Quality of Original and Biosimilar Epoetin Products
Files
Publication date
2011
Authors
Brinks, Vera
Hawe, A.
Basmeleh, A.H.H.
Joachin-Rodriguez, L.
Haselberg, R.
Somsen, Govert
Jiskoot, Wim
Schellekens, Huub
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Purpose: To compare the quality of therapeutic erythropoietin (EPO) products, including two biosimilars, with respect to content, aggregation, isoform profile and potency. Methods: Two original products, Eprex (epoetin alfa) and Dynepo (epoetin delta), and two biosimilar products, Binocrit (epoetin alfa) and Retacrit (epoetin zeta), were compared using (1) high performance size exclusion chromatography, (2) ELISA, (3) SDS-PAGE, (4) capillary zone electrophoresis and (5) in-vivo potency. Results: Tested EPO products differed in content, isoform composition, and potency. Conclusion: Of the tested products, the biosimilars have the same or even better quality as the originals. Especially, the potency of originals may significantly differ from the value on the label.
Keywords
Farmacie/Biofarmaceutische wetenschappen (FARM), Medical technology, Farmacie(FARM), Bescherming en bevordering van de menselijke gezondheid, Biomedische technologie en medicijnen, Public Health, Analytical chemistry, Pharmacology, Drugmisbruik en verslaving, SDG 3 - Good Health and Well-being
Citation
Brinks, V, Hawe, A, Basmeleh, A H H, Joachin-Rodriguez, L, Haselberg, R, Somsen, G W, Jiskoot, W & Schellekens, H 2011, 'Quality of Original and Biosimilar Epoetin Products', Pharmaceutical Research, vol. 28, no. 2, pp. 386-393. https://doi.org/10.1007/s11095-010-0288-2